Dr. Dahyeon Kang is an Assistant Professor at the University of Washington School of Medicine. She earned her doctoral degree from the University of Illinois at Urbana-Champaign, where her work focused on the etiology of alcohol and substance use disorders through multimodal research methods, including alcohol administration, neuroimaging, transdermal biosensors, and ecological momentary assessments. At the University of Washington’s Department of Psychiatry, Dr. Kang investigates how individual and social factors interact to influence alcohol and cannabis use behaviors.
My research focuses on improving clinical outcome measures and intervention outcomes for individuals with Down syndrome, neurodevelopmental disorders, and other special healthcare needs. I conduct research in real-world, clinical settings using multiple different tools, including caregiver-report, behavioral assessments, and electroencephalography (EEG) to study the development of and interventions for challenging behaviors. I am currently a KL2 INCLUDE Scholar conducting research on cognitive abilities and challenging behaviors in youth with Down syndrome.
I am currently the Medical Director at the Garvey Institute Center for Neuromodulation and am providing leadership to help grow our portfolio in the area of Neuromodulation and Interventional Psychiatry. Before coming to the UW, I was the Muriel Harris Chair of Geriatric Psychiatry and Professor of Clinical Psychiatry at UCLA. While at UCLA, I held many administrative, clinical and teaching leadership positions including serving as Medical Director of Inpatient Geriatric Psychiatry, Chief of Staff of the UCLA Neuropsychiatric Hospital, Founding Faculty of the UCLA Neuromodulation Division, Medical Director of the ECT and Interventional Psychiatry Program, among others.
I recently became Editor-in-Chief of the Journal of ECT and Related Therapies, the official publication of the International Society of ECT and Neurostimulation. My research projects have included investigating various neuromodulation and interventional therapies and developing novel educational programs and curricula. I have an abiding interest in mentoring and helping faculty at the start of their careers and a commitment to fostering the advancement of women and underrepresented minority (URM) faculty in academic medicine.
My clinical and research interests center around behavioral and psychological symptoms that present in neurodegenerative diseases, especially dementias. Though dementia is well-known to affect one’s memory and cognition, over 90% of people with dementia develop new neuropsychiatric symptoms – including apathy, dysphoria. anxiety, aggression, agitation, disinhibition, hallucinations, and delusions. Despite the ubiquity of these symptoms, very little is known about how they develop in dementia. My research interests are in understanding more about the molecular and cellular mechanisms of neuropsychiatric symptoms in dementia beyond the well-studied changes associated with cognitive deficits.
Along with my research mentor Martin Darvas PhD (Department of Laboratory Medicine and Pathology), we employ numerous approaches to better understand these neuropsychiatric symptoms, including techniques involving transcriptomic analyses of human and mouse post-mortem tissue, development and implementation of biomarkers derived from human and animal model fluids (plasma, serum, cerebrospinal fluid), virally-mediated gene manipulations, animal modeling of cognitive and neuropsychiatric phenotypes, and basic cellular and molecular biology techniques.
I am a behavioral neuroscientist who earned my PhD from Rutgers University and completed a postdoc here, in the Psychiatry and Behavioral Sciences Department at the University of Washington. My lab, located in the MIRECC at VA Puget Sound, aims to identify the neural mechanisms underlying substance use disorders and maladaptive decision making.
My primary focus is studying the neurobiological consequences and predictors of chronic fentanyl use. To accomplish this, I utilize cutting-edge in-vivo optical neuroscience tools (photometry, optogenetics, miniscopes) along with a newly developed oral-fentanyl self-administration model for rats and mice. I am also the lead developer for DeepSqueak, a popular software package for bioacoustics analysis that integrates machine-vision algorithms with an intuitive graphical interface to accelerate animal communication research.
Anna Sunshine completed her medical school, graduate school and psychiatry training at the University of Washington. Her graduate training was completed in the Department of Genome Sciences where she used high-throughput sequencing approaches to study the biological effects of complex genetic changes in the model organism Saccharomyces cerevisiae.
Connecting her background in genomics with psychiatry, Dr. Sunshine’s research now focuses on identifying genetic risk factors for schizophrenia and characterizing the biological effects of these risk alleles using induced pluripotent stem cell (iPSC) systems. Dr. Sunshine engages individuals living with schizophrenia and their families in research to further our current understanding of schizophrenia biology and help lay groundwork for future treatment development.
Dr. Michael Schrift is a Professor in the Department of Psychiatry and Behavioral Sciences at the University of Washington. He currently is an attending neuropsychiatrist at the Brain & Memory Center at Harborview Medical Center. He is he the director of the Behavioral Neurology/Neuropsychiatry Fellowship Training Program. He previously was the Division Director of Geriatric Psychiatry & Neuropsychiatry in the Department of Psychiatry and Behavioral Sciences at Northwestern University Feinberg School of Medicine in Chicago. He was also the director of the fellowship training program in Geriatric Psychiatry, co-director of the Clinical Neuroscience Fellowship program, and the director of the Neuromodulation Program and the Cancer Neuropsychiatry Program. He has many years of experience treating patients with Parkinson’s disease, Huntington’s disease, and Wilson’s, among other neuropsychiatric disorders. He also is an attending neuropsychiatrist in the Harborview Memory and Brain Wellness Clinic.
Dr. Schrift is the Book Review Editor for the Journal of Neuropsychiatry and Clinical Neurosciences.
He is board-certified in Psychiatry by the American Board of Psychiatry and Neurology as well as board certified in Behavioral Neurology and Neuropsychiatry by the United Council for Neurologic Subspecialties. He has training in Bioethics and serves on the ethics committee at Harborview Medical Center. Dr. Schrift is a fellow of the American Neuropsychiatric Association.
The Hendrickson research group explores underlying biological mechanisms related to the development and maintenance of posttraumatic stress disorder (PTSD) and related conditions, including mild traumatic brain injury, as well as the potential for interaction between different types of stress and trauma. Through the design and implementation of translational clinical studies, we apply this work directly to the pursuit of new treatment options for people who have experienced a traumatic stress.
A primary goal of our team is to understand broadly the ways traumatic stress interferes with people’s lives, and to prioritize the areas of greatest clinical need. We look for ways to prevent persistent symptoms after trauma, to match patients more quickly to the treatment options that will be most effective for them as individuals, and to develop new treatment options for those for whom current options are simply not adequate.
In addition to my research work, I am a staff psychiatrist in the VA PTSD Outpatient Clinic and a member of the VA Dialectical Behavioral Therapy (DBT) Team, and provide teaching and mentorship for residents in the UW Psychiatry Training Program.
Personal Statement
My research focuses on understanding the development of neural circuits that contributing to and underlie social development. Our lab uses a number of different tools: primarily electroencephalography (EEG) and event-related potentials (ERPs), but also eye tracking, cardiophysiology (EKG), neuroimaging, and behavioral measures to study how infants, children, and adults perceive, attend and learn about their social environment. Our projects also focus on the development and validation of biomarkers that may be used to understand the course of development and treatment response in children with disruption in social and communication function such as autism spectrum disorder, 16p11.2 deletion syndrome, and other neurodevelopmental disorders.
